Does IBIO pay a dividend and is it safe?

iBio Inc. (IBIO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / IBIO / dividends

GANX (41) SER (31) HYPD (38) CNTB (26) ⌘ Pro Terminal →

iBio Inc. (IBIO) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is IBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

IBIO last traded at $0.80 (+4.06% on volume of 307,120 shares), positioning the stock -25.23% below its 50-day simple moving average ($1.07) and -52.38% below its 200-day simple moving average ($1.68). Across its 52-week range of $0.69 to $3.82, IBIO sits at the 3.5% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.90).

$0.80 +4.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.80

iBio Inc. (IBIO) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $49.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IBIO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, iBio Inc. (NASDAQ: IBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.80 (+4.06% 1D, market cap $49.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1016 tracked Health Care issuers, IBIO ranks #952 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IBIO compare to GANX and SER in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IBIO carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GANX (Gain Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M) and SER (Serina Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, IBIO leads on earnings multiple (N/A) while IBIO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IBIO?

▼

Per IBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001420720), iBio Inc. generated $400.0K in revenue (+77.8% YoY), -$18.4M in net income, and -$15.3M in free cash flow against $64.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.80 (+0.54%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IBIO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY IBIO SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (26% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 37 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (22% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.78+5.1% Next Q

Q2 (-2Q)

Grade E$0.82-6.1% Next Q

Q3 (-1Q)

Grade E$0.77+3.9% Next Q

Current

Grade E$0.80-11.1% Hist 90D α

Trajectory: E (15) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IBIO currently carries a cautious 23/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.07) and Max Pain ($0.84) forces dealer call-delta covering toward $4.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IBIO Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IBIO)

✓Walkthrough of IBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.37%▼ DESCENDING CHANNEL

2026-11-03O $0.81H $0.81L $0.77C $0.80VOL 214.3K

RES: $1.19SUP: $0.58SMA50: $1.07SMA200: $1.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IBIO Butterfly Map → + Track IBIO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +77.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IBIO)

Health Care Rank #952 of 1016 ⚔️ GANX vs IBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IBIO vs. GANX, SER, HYPD, CNTB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, iBio Inc. (IBIO) ranks #952 by composite RQD confidence (23/100, grade E) and #746 by equity capitalization ($49.4M). Within this direct 5-issuer industry benchmark cohort, IBIO leads on earnings valuation at N/A trailing P/E, while IBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with IBIO at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IBIO ACTIVE iBio Inc.	E	23/100	—	—	-35.0%	+4.06%	$49.4M	Benchmark Subject
GANX Gain Therapeutics Inc.	D-	41/100	—	—	-35.0%	0.00%	$49.3M	/ganx-vs-ibio →
SER Serina Therapeutics Inc.	E	31/100	—	—	-35.0%	-4.64%	$49.3M	/ser-vs-ibio →
HYPD Hyperion DeFi Inc.	D-	38/100	—	62.7%	-35.0%	-7.76%	$49.7M	/hypd-vs-ibio →
CNTB Connect Biopharma Holdings Limited	E	26/100	—	—	-35.0%	-3.13%	$50.5M	/cntb-vs-ibio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001420720 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), iBio Inc. (IBIO) reported GAAP revenue of $400.0K (+77.8% vs. FY2024 revenue of $225.0K , and -99.5% cumulative change since FY2023) , GAAP net income of -$18.4M, operating cash flow of -$15.3M, and free cash flow of -$15.3M (+18.4% YoY). On the balance sheet, IBIO closed FY2025 with $64.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$400.0K	-$18.4M	-$15.3M	-$15.3M	$64.4M	—
FY2024 (FY)	2024-06-30	$225.0K	-$24.9M	-$18.6M	-$18.8M	$21.7M	—
FY2023 (FY)	2023-06-30	$82.2M	-$65.0M	-$30.4M	-$30.4M	—	—

3. IBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IBIO compare to GANX and SER in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IBIO?

Where is IBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

IBIO last traded at $0.80 (+4.06% on volume of 307,120 shares), positioning the stock -25.23% below its 50-day simple moving average ($1.07) and -52.38% below its 200-day simple moving average ($1.68). Across its 52-week range of $0.69 to $3.82, IBIO sits at the 3.5% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.90).

Direct Sub-Reports: IBIO RQD Cockpit IBIO 12M Forecast IBIO Earnings & Move IBIO Dividends & DRIP IBIO Insiders & 13F IBIO Whale Options IBIO Profit Sankey IBIO News & Why

ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ SEC XBRL & RQD VERIFIED

IBIO — iBio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

iBio Inc. (IBIO) earns a live Roarable RQD composite score of 23/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.80 (+4.06% 1D, market capitalization $49.4M).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (4/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

The profile identifies iBio Inc. As a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile reports market capitalization of $0.1B, which is consistent with the $52.3M figure in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), iBio Inc. (IBIO) reported $400.0K in annual revenue (up from $225.0K in FY2024, +77.8% YoY) and -$18.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($82.2M revenue, -$65.0M net income) through FY2025, IBIO scaled operating cash flow to -$15.3M and free cash flow to -$15.3M, backed by $64.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 23/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.69 – $3.82 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The Butterfly Supply-Chain Graph lists no upstream or downstream links, no sector correlations, and no proprietary signals.. An investor should note the absence of mapped ripples rather than assume any.

Key Question #1: Can IBIO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $400.0K and free cash flow of -$15.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is IBIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for iBio Inc. (IBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IBIO Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 20h ago

iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - Slideshow (NASDAQ:IBIO) 2026-10-07

Seeking Alpha report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 23h ago

iBio, Inc. Stock 12‑Month Price Target Raised to $5.6, Implies 509% Upside

TradingView report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

iBio Shareholders Approve Governance and Capital Structure Changes

The Globe and Mail report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH BioPharm International • 1d ago

Bio’s Activin E Antibody IBIO-610 Shifts Semaglutide Weight Loss Toward Fat in Obese Primates

BioPharm International report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 1d ago

iBio, Inc. Stock 12‑Month Price Target Cut to $5.53, Implies 447% Upside

TradingView report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A director receives 38,000 iBio (IBIO) stock options with a $0.78 exercise price.

Stock Titan report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

iBio, Inc. (NASDAQ:IBIO) Stock Has Average Price Target of $6.00 According to Analysts

MarketBeat report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Tuesday's Intraday Session - SCWorx (NASDAQ:WORX), Myriad Genetics (NASDA

Benzinga report covering iBio Inc. (IBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IBIO Bull vs. Bear Conversation Board — What's Your Call at $0.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IBIO 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $0.97 (+26.0%)

📌 Pinned Debate

Two third-party price target actions (raised to $5.6, implying 509% upside) point to analyst optimism that the stock's current $0.81 pr

Long IBIO at $0.77 targeting $0.97. Two third-party price target actions (raised to $5.6, implying 509% upside) point to analyst optimism that the stock's current $0.81 price is well below its estimated value.. Institutional whale score is 4/20 and the risk/reward vs. the $0.69 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@SkepticalCFA Shorting a 4/20 institutional whale-flow stock at $0.77 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.61 (-20.8%)

Spot @ $0.77

A -35% ROIC, 0% FCF yield, Altman Z of 0.2, and -60% operating margin indicate the business is not generating cash and carries elevated

Sitting on the sidelines or leaning short IBIO above $0.77. A -35% ROIC, 0% FCF yield, Altman Z of 0.2, and -60% operating margin indicate the business is not generating cash and carries elevated distress risk.. Until Fundamental Cash Engine (3/20) and FCF yield (0.0%) inflect higher, upside is capped near $3.82.